An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3065-3069

  Hay, A E ^a   Klimm, B ^b   Chen, B E ^a   Goergen, H ^b   Shepherd, L E ^a   Fuchs, M ^b   Gospodarowicz, M K ^c   Borchmann, P ^b   Connors, J M ^d   Markova, J ^e   Crump, M ^f   Lohri, A ^g   Winter, J N ^h   Dorken B ⁱ   Pearcey, R G ^j   Diehl, V ^b   Horning, S J ^k   Eich, H T ^l   Engert, A ^b   Meyer, R M ^m  

^a Queen's Cancer Research Institute   (Canada)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF TORONTO   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY OF TORONTO   (Canada)

^g SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF ALBERTA   (Canada)

^k STANFORD UNIVERSITY   (United States)

^l UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^m JURAVINSKI CANCER CENTRE   (Canada)

more..

Author keywords

Chemotherapy; Clinical trial; Combined modality therapy; Hodgkin lymphoma; Progression free survival; Radiation therapy

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; EXPLORATORY RESEARCH; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CHEMOTHERAPY; CLINICAL TRIAL; COMBINED MODALITY THERAPY; HODGKIN LYMPHOMA; PROGRESSION-FREE SURVIVAL; RADIATION THERAPY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HODGKIN DISEASE; HUMANS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINBLASTINE;

EID: 84888771421     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt389     Document Type: Article

References (19)

1. Meyer RM, Hoppe RT. Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. Blood 2012; 120(23): 4488-4495.
2. Eichenauer DA, Engert A, Dreyling M. On behalf of the ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(SUPPL 6): vi55-vi58.
3. Hoppe RT, Advani RH, Ai WZ et al. Hodgkin lymphoma. J Natl Compr Cancer Netw 2011; 9(9): 1020-1058.
4. Engert A, Plutschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363(7): 640-652.
5. Eich HT, Diehl V, Goergen H et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 Trial. J Clin Oncol 2010; 28(27): 4199-4206.
6. Meyer RM, Gospodarowicz MK, Connors JM et al. ABVD alone versus radiationbased therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2011; 366(5): 399-408.
7. Meyer RM, Gospodarowicz MK, Connors JM et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23 (21): 4634-4642.
8. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5): 579-586.
9. Sasse S, Klimm B, Goergen H et al. Comparing long-term toxicity and efficacy of combined modality treatment including extended-or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann Oncol 2012; 23(11): 2953-2959.
10. Bonadonna G, Bonfante V, Viviani S et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22(14): 2835-2841.
11. NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. NCCN 2013; (Version II) http://www.nccn.org (13 August 2013, date last accessed).
12. Girinsky T, van der Maazen R, Specht L et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol 2006; 79(3): 270-277.
13. Andre MP, Reman O, Federico M et al. Interim analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin lymphoma. ASH Annual Meeting Abstracts 2012; 120(21): 549.
14. Girinsky T, Pichenot C, Beaudre A et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkins disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?. Int J Radiat Oncol Biol Phys 2006; 64(1): 218-226.
15. Chera BS, Rodriguez C, Morris CG et al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and threedimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75(4): 1173-1180.
16. Sawyer DB. Anthracyclines and heart failure. N Engl J Med 2013; 368(12): 1154-1156.
17. Radford J, Barrington S, Counsell N et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts 2012; 120(21): 547.
18. Engert A, Ballova V, Haverkamp H et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's study group. J Clin Oncol 2005; 23(22): 5052-5060.
19. Pfirrmann M, Hochhaus A, Lauseker M et al. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 2011; 25(9): 1433-1438.